Ziltivekimab’s Phase 3 Failure Shatters Hopes for Inflammation-Targeting Cardiovascular Drugs, Triggering Widespread Biotech Market Decline.
The biopharmaceutical sector was rocked on July 31, 2026, as Novo Nordisk announced the disappointing...
Knowledge and News for the Global Fight Against Cancer.
The biopharmaceutical sector was rocked on July 31, 2026, as Novo Nordisk announced the disappointing...
Pharmaceutical giant Johnson & Johnson has taken a significant step into the burgeoning field of...
Cambridge, MA – Alnylam Pharmaceuticals, a pioneering force in RNA interference (RNAi) therapeutics, experienced a...
In a pivotal decision that could redefine treatment pathways for a challenging subset of melanoma...
A federal lawsuit filed in California has cast a significant shadow over Hims & Hers,...
Vertex Pharmaceuticals, a biopharmaceutical giant predominantly known for its transformative cystic fibrosis treatments, has officially...
Despite announcing positive results from a pivotal Phase 2b study for its experimental schizophrenia medicine...
In a closely watched decision that underscores the complex and often contentious landscape of rare...
The dynamic landscape of biotechnology witnessed a significant strategic shift this week as two burgeoning...
The intricate journey of bringing scientific breakthroughs from the laboratory to patients worldwide is fraught...